NCT01939977 - Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation. | Biotech Hunter

Enrollment

148

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

December 31, 2015

Conditions

Secondary Hyperparathyroidism Due to Renal Causes

Interventions

DRUG

Paricalcitol

1 capsule/day for 6 months. On Month 1 and Month 3 it can be increased up to 2 capsules/day or decreased down to 1 capsule/48 hours.

DRUG

Calcifediol

5 drops/day during 6 months. On Month 1 it can be increased up to 7 drops/day. If this occurs then, on Month 3, it can decreased to 5 drops/day or continue 7 drops/day until end of treatment.

Trial Locations (16)

11009

Hospital Puerta Del Mar, Cadiz

14004

Hospital Reina Sofía, Córdoba

15006

Complexo Hospitalario Universitario A Coruna, A Coruña

28034

Hospital Ramón Y Cajal, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

29010

Complejo Hospitalario Regional de Málaga, Málaga

38320

Complejo Hospitalario Universitario de Canarias, Las Palmas de Gran Canaria

39008

Hospital Universitario Marqués de Valdecilla, Santander

41013

Hospital Virgen Del Rocío, Seville

46026

Hospital Universitari I Politècnic La Fe, Valencia

50009

Hospital Universitario Miguel Servet, Zaragoza

08916

Hospital Universitari Germans Trias I Pujol de Badalona, Badalona

08907

Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat

08003

Hospital Del Mar, Barcelona

08025

Fundació Puigvert-Iuna, Barcelona

08035

Hospital Universitari Vall D'Hebron, Barcelona